

Product datasheet for **TL306398V**

BIN1 Human shRNA Lentiviral Particle (Locus ID 274)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	BIN1 Human shRNA Lentiviral Particle (Locus ID 274)
Locus ID:	274
Synonyms:	AMPH2; AMPHL; CNM2; SH3P9
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	BIN1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	<u>NM_004305</u> , <u>NM_139343</u> , <u>NM_139344</u> , <u>NM_139345</u> , <u>NM_139346</u> , <u>NM_139347</u> , <u>NM_139348</u> , <u>NM_139349</u> , <u>NM_139350</u> , <u>NM_139351</u> , <u>NM_001320632</u> , <u>NM_001320633</u> , <u>NM_001320634</u> , <u>NM_001320640</u> , <u>NM_001320641</u> , <u>NM_001320642</u> , <u>NM_139350.1</u> , <u>NM_139350.2</u> , <u>NM_139348.1</u> , <u>NM_139348.2</u> , <u>NM_139343.1</u> , <u>NM_139343.2</u> , <u>NM_139346.2</u> , <u>NM_139349.1</u> , <u>NM_139349.2</u> , <u>NM_139345.1</u> , <u>NM_139345.2</u> , <u>NM_139344.1</u> , <u>NM_139344.2</u> , <u>NM_004305.1</u> , <u>NM_004305.3</u> , <u>NM_139347.1</u> , <u>NM_139347.2</u> , <u>NM_139351.1</u> , <u>NM_139351.2</u> , <u>BC004101</u> , <u>BM711160</u> , <u>BM742027</u> , <u>BM805510</u> , <u>NM_139346.3</u> , <u>NM_139351.3</u> , <u>NM_139347.3</u> , <u>NM_004305.4</u> , <u>NM_139348.3</u> , <u>NM_139349.3</u> , <u>NM_139345.3</u> , <u>NM_139344.3</u> , <u>NM_139350.3</u> , <u>NM_139343.3</u>
UniProt ID:	<u>O00499</u>
Summary:	This gene encodes several isoforms of a nucleocytoplasmic adaptor protein, one of which was initially identified as a MYC-interacting protein with features of a tumor suppressor. Isoforms that are expressed in the central nervous system may be involved in synaptic vesicle endocytosis and may interact with dynamin, synaptojanin, endophilin, and clathrin. Isoforms that are expressed in muscle and ubiquitously expressed isoforms localize to the cytoplasm and nucleus and activate a caspase-independent apoptotic process. Studies in mouse suggest that this gene plays an important role in cardiac muscle development. Alternate splicing of the gene results in several transcript variants encoding different isoforms. Aberrant splice variants expressed in tumor cell lines have also been described. [provided by RefSeq, Mar 2016]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).